Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with
or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
The names of the study interventions involved in this study are:
- Sacituzumab govitecan (IMMU-132)
- Pembrolizumab (Keytruda®; MK-3475)
Phase:
Phase 2
Details
Lead Sponsor:
Sara Tolaney
Collaborators:
Gilead Sciences Immunomedics, Inc. Merck Sharp & Dohme Corp.